Physician profile
Caylen Cable
NPI 1881160794
$2,292.82
in general payments reported to CMS, 2019-2025
34 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.74 · 2022: $262 · 2023: $895 · 2024: $880 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.44 |
| Education | $249.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.10 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $277.39 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $220.47 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $212.37 | 2023-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals Lp | $190.64 | 2023-2025 | Lynparza, Enhertu, Bevespi Aerosphere |
| Janssen Biotech, INC. | $129.43 | 2022-2024 | Darzalex, Imbruvica, Rybrevant |
| Lilly USA, LLC | $113.57 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| Eisai INC. | $64.02 | 2023-2024 | |
| Celgene Corporation | $59.46 | 2023-2024 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $44.46 | 2023-2024 | Rezlidhia, Tavalisse |
| Pharmacosmos Therapeutics INC. | $41.88 | 2023 | Monoferric |
| Pharmaessentia USA Corporation | $39.63 | 2023 | Besremi |
| Mirati Therapeutics, INC. | $35.44 | 2023 | Krazati |
| Genentech USA, INC. | $34.99 | 2024 | Tecentriq, Alecensa, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $33.69 | 2024 | Fruzaqla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.00 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $30.45 | 2022-2024 | |
| Daiichi Sankyo INC. | $29.95 | 2023 | Enhertu |
| Exelixis INC. | $29.74 | 2023 | Cabometyx |
| Beigene USA, INC. | $28.78 | 2022-2024 | Brukinsa |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.63 | 2022 | |
| Amgen INC. | $22.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.49 | 2024 | Opdivo |
| Sobi, INC | $20.79 | 2023 | |
| Phathom Pharmaceuticals, INC. | $20.33 | 2025 | Voquezna |
| Gilead Sciences, INC. | $19.73 | 2023 | |
| Horizon Therapeutics Plc | $19.40 | 2022 | |
| Morphosys, US INC. | $19.14 | 2023 | Monjuvi |
| Livanova USA, INC. | $19.08 | 2022 | |
| Servier Pharmaceuticals LLC | $19.07 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2025 | |
| Radius Health, INC. | $16.22 | 2025 | Tymlos |
| Genmab U.S., INC. | $15.87 | 2023 | Tivdak |
| Janssen Pharmaceuticals, INC | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caylen Cable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.